Catalyst Pharmaceuticals announced the online publication in Sage Open Medicine of the results of an investigator-sponsored Phase IIb clinical trial evaluating Firdapse for the treatment of MuSK antibody positive Myasthenia Gravis, or MuSK-MG. The positive topline results from this trial were previously announced, but the full results of safety, efficacy and other clinical data are now available. The MSK-001 trial was a randomized, double-blind, placebo-controlled, double crossover design. The co-primary endpoints were statistically met as well as the secondary endpoints. The study provided evidence that amifampridine phosphate was safe and effective in treating MuSK-MG patients. The study was conducted in Milan, Italy.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.